Case of a Patient with Acute Myeloid Leukemia Published in the Journal ‘Leukemia’ 

HONG KONG – OrbusNeich today announced the publication of a case report stating that use of the Genous Stent in combination with the anticoagulant bivalirudin may represent a safe and efficacious treatment strategy for the management of acute coronary syndrome (ACS) in high-risk patients with contraindications to long-term dual antiplatelet therapy (DAPT). The case of a patient with acute myeloid leukemia (AML) undergoing emergency percutaneous coronary intervention (PCI) for ACS-non-ST elevation myocardial infarction (NSTEMI) was published in a recent issue of Leukemia.

“Anemia, thrombocytopenia and abnormal white blood cell counts due to the replacement of normal bone marrow with leukemic cells increases bleeding risk in patients requiring antithrombotic therapy,” said Dr. Gennaro Galasso, Department of Clinical Medicine, Cardiovascular Science and Immunology, Federico II University of Naples, Italy. “For patients with hematological cancers who require cardiac intervention, this risk creates a significant clinical challenge. In this case we show that the Genous Stent in combination with bivalirudin was a safe and effective treatment strategy for an NSTEMI patient with AML. In addition, the pro-healing technology of the Genous Stent enabled the early discontinuation of DAPT at 15 days so that the patient could commence chemotherapy as quickly as possible.”

The patient, a 69-year-old male, was diagnosed with multiple critical stenoses on the proximal and middle segment of the left anterior descending coronary artery (LAD) and a chronic total occlusion (CTO) of the right coronary artery. A Genous Stent was implanted into the proximal-medium portion of the LAD. The patient received bivalirudin with a loading dose of 0.75 mg/kg and an infusion of 1.75 mg/kg/h up to two hours after the procedure. Bivalirudin, a thrombin-specific anticoagulant, has previously been shown to reduce bleeding incidence in patients with acquired thrombocytopenia. At 30 days following PCI, no cardiovascular event or bleeding complication was reported. The patient was discharged after the first cycle of chemotherapy.

Source: OrbusNeich